TG Therapeutics Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: tgtherapeutics.com
Recent Analyst Ratings for TG Therapeutics Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $50.00 | Buy | TD Cowen |
| 8/2/2023 | $16.00 → $12.00 | Sell → Neutral | Goldman |
| 6/26/2023 | $55.00 → $40.00 | Buy | Jefferies |
| 5/20/2022 | $5.00 | Underperform | BofA Securities |
| 2/23/2022 | $49.00 → $35.00 | Buy | B. Riley Securities |
| 1/28/2022 | $70.00 → $68.00 | Buy | HC Wainwright & Co. |
| 1/24/2022 | $75.00 → $70.00 | Buy | HC Wainwright & Co. |
| 12/1/2021 | $55.00 → $36.00 | Outperform | Evercore ISI Group |
| 12/1/2021 | $26.00 → $13.00 | Sell | Goldman Sachs |
| 12/1/2021 | $84.00 → $75.00 | Buy | HC Wainwright & Co. |
TG Therapeutics Inc. Press Releases
Fastest customizable press release news feed in the world
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting, being held April 5 - 9, 2025, in San Diego, California. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below. TG PRESENTATIONS: Poster Presentation Title: No Association Between Decreases in Serum Immunoglobulin (Ig) Levels
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated,
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We are pleased to share data at this year's ACTRIMS annual meeting including updated data from the ENHANCE trial, which aims to ex
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the fourth quarter and full year 2024 and to provide a business outlook for 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An a
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the schedule of presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) to be presented at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 27 – March 1, 2025, in West Palm Beach, Florida. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the upcoming presentations are outlined below. TG PRESENTATIONS:P
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), yesterday announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2024 (unaudited), as well as financial guidance and development milestones for 2025, during a preannounced presentation at the 43rd Annual J.P Morgan Healthcare Conference. An audio repl
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 13, 2025, at 4:30 PM PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG's website following the event. ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical compa
TG Therapeutics to Participate in the Evercore HealthCONx Conference
NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 7th Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events. ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company fo
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The Company's growth between fiscal years 2020 to 2023 was fueled by BRIUMVI® revenues, which was approved to treat adult individuals with relapsing forms of multiple sclerosis in December of 2022. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, "We are proud to be recognized as the fastest-growing c
FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics
HOLLY SPRINGS, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Diosynth Biotechnologies (the Company), a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, today announced that TG Therapeutics, Inc. (NASDAQ:TGTX) has committed to a multi-year manufacturing supply agreement for BRIUMVI® (ublitiximab-xiiy), its U.S. FDA-approved therapeutic for relapsing forms of multiple sclerosis (RMS). Under the terms of the manufacturing supply agreement, FUJIFILM Diosynth Biotechnologies will provide secondary US-based manufacturing supply for BRIUMVI at the Company's new biopharmaceutical manufacturing facility
TG Therapeutics Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
TD Cowen initiated coverage on TG Therapeutics with a new price target
TD Cowen initiated coverage of TG Therapeutics with a rating of Buy and set a new price target of $50.00
TG Therapeutics upgraded by Goldman with a new price target
Goldman upgraded TG Therapeutics from Sell to Neutral and set a new price target of $12.00 from $16.00 previously
Jefferies resumed coverage on TG Therapeutics with a new price target
Jefferies resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $40.00 from $55.00 previously
BofA Securities initiated coverage on TG Therapeutics with a new price target
BofA Securities initiated coverage of TG Therapeutics with a rating of Underperform and set a new price target of $5.00
B. Riley Securities reiterated coverage on TG Therapeutics with a new price target
B. Riley Securities reiterated coverage of TG Therapeutics with a rating of Buy and set a new price target of $35.00 from $49.00 previously
HC Wainwright & Co. reiterated coverage on TG Therapeutics with a new price target
HC Wainwright & Co. reiterated coverage of TG Therapeutics with a rating of Buy and set a new price target of $68.00 from $70.00 previously
HC Wainwright & Co. reiterated coverage on TG Therapeutics with a new price target
HC Wainwright & Co. reiterated coverage of TG Therapeutics with a rating of Buy and set a new price target of $70.00 from $75.00 previously
Evercore ISI Group reiterated coverage on TG Therapeutics with a new price target
Evercore ISI Group reiterated coverage of TG Therapeutics with a rating of Outperform and set a new price target of $36.00 from $55.00 previously
Goldman Sachs reiterated coverage on TG Therapeutics with a new price target
Goldman Sachs reiterated coverage of TG Therapeutics with a rating of Sell and set a new price target of $13.00 from $26.00 previously
HC Wainwright & Co. reiterated coverage on TG Therapeutics with a new price target
HC Wainwright & Co. reiterated coverage of TG Therapeutics with a rating of Buy and set a new price target of $75.00 from $84.00 previously
TG Therapeutics Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Director Hume Daniel gifted 62,459 shares, decreasing direct ownership by 26% to 178,030 units (SEC Form 4)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
Director Charney Laurence N gifted 6,000 shares, decreasing direct ownership by 3% to 201,479 units (SEC Form 4)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
CEO Weiss Michael S was granted 750,000 shares, increasing direct ownership by 6% to 13,824,929 units (SEC Form 4)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
CFO Power Sean A was granted 87,500 shares, increasing direct ownership by 14% to 708,111 units (SEC Form 4)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
CFO Power Sean A sold $629,382 worth of shares (21,358 units at $29.47), decreasing direct ownership by 3% to 660,611 units (SEC Form 4)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
Director Lonial Sagar sold $152,200 worth of shares (5,000 units at $30.44), decreasing direct ownership by 5% to 100,195 units (SEC Form 4)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
Director Charney Laurence N sold $754,875 worth of shares (25,000 units at $30.20) and gifted 5,000 shares, decreasing direct ownership by 13% to 207,479 units (SEC Form 4)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
Director Echelard Yann sold $489,600 worth of shares (20,000 units at $24.48), decreasing direct ownership by 8% to 224,098 units (SEC Form 4)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
Director Lonial Sagar sold $432,889 worth of shares (25,933 units at $16.69) and was granted 22,250 shares, decreasing direct ownership by 3% to 105,195 units (SEC Form 4)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
Director Hume Daniel was granted 22,250 shares, increasing direct ownership by 10% to 240,489 units (SEC Form 4)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
TG Therapeutics Inc. SEC Filings
SEC Form 10-K filed by TG Therapeutics Inc.
10-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
TG Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
TG Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by TG Therapeutics Inc.
SCHEDULE 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SEC Form 10-Q filed by TG Therapeutics Inc.
10-Q - TG THERAPEUTICS, INC. (0001001316) (Filer)
TG Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
SEC Form 10-Q filed by TG Therapeutics Inc.
10-Q - TG THERAPEUTICS, INC. (0001001316) (Filer)
Amendment: SEC Form 10-K/A filed by TG Therapeutics Inc.
10-K/A - TG THERAPEUTICS, INC. (0001001316) (Filer)
TG Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
TG Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
TG Therapeutics Inc. FDA approvals
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:
FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:
FDA Approval for UKONIQ
Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-2) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity
FDA Approval for UKONIQ
Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity
FDA Approval for UKONIQ
Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-2) with active ingredient UMBRALISIB has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity
FDA Approval for UKONIQ
Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity
TG Therapeutics Inc. Leadership Updates
Live Leadership Updates
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
TG Therapeutics Inc. Financials
Live finance-specific insights
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated,
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the fourth quarter and full year 2024 and to provide a business outlook for 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An a
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ET NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with recent company developments and provided an update on 2024 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, "The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are excited to
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million Cash flow positive for second quarter 2024 Establishes $250 million credit facility to repay existing debt and to buy back up to $100 million of common stock under a share repurchase program Initiated phase 1 study in RMS patients for subcutaneous ublituximab and received FDA IND clearance to study azer-cel (allogeneic CD19 CAR-T) in patients with progressive MS Conference call to be held today, August 6, 2024, at 8:30 AM ET NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therape
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the second quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Second Quarter Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An au
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2024, representing >25% growth quarter over quarter Conference call to be held today, May 1, 2024, at 8:30 AM ET NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive O
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET to discuss results for the first quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter Update Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively Conference call to be held today, February 28, 2024, at 8:30 AM ET NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and year ended December 31, 2023, along with recent company developments.Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "2023 was an exciting year of execution for TG, which we believe has set the stage for a successful 2024. The BRIUMVI launch exceeded our expectations, and we ended the year with app
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Wednesday, February 28, 2024, at 8:30 AM ET to discuss results for the fourth quarter and year-end 2023 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Fourth Quarter and Year End Update Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's websit
TG Therapeutics Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SEC Form SC 13G filed by TG Therapeutics Inc.
SC 13G - TG THERAPEUTICS, INC. (0001001316) (Subject)
SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)